title: Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
abstract: The Melan-A/MART-1 gene product is frequently recognized by tumor-specific HLA-A2-restricted CTL. An immunodominant nonapeptide has been localized to the region spanning residues 27-35. However, the decapeptide including residues 26-35 (the nonapeptide extended NH2 terminally by one residue) appeared to be recognized as efficiently as the nonapeptide. In this study, we show that the optimal length immunodominant peptide appears to correspond to the decapeptide 26-35, as assessed by quantitative analyses of both 4 polyclonal and 13 monoclonal populations of specific CTL. Functional assays of peptide binding to HLA-A2 indicate that the decapeptide is significantly a more efficient binder than the nonapeptide. Moreover, analogues of the decapeptide including substitutions at a secondary HLA-A2 peptide anchor further improve decapeptide binding. Finally, we show that the functional (9 CTL clones analyzed) and structural TCR repertoire (7 CTL clones) of a group of specific CTL clones is rather diverse. The findings reported here may have important implications for future peptide-based melanoma vaccination trials as well as for the monitoring of specific CTL responses in vivo.
authors.affiliation: Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Hospitalier Universitaire Vaudois Centre, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: Romero
authors.forename: N
authors.initials: N
authors.lastname: Gervois
authors.forename: J
authors.initials: J
authors.lastname: Schneider
authors.forename: P
authors.initials: P
authors.lastname: Escobar
authors.forename: D
authors.initials: D
authors.lastname: Valmori
authors.forename: C
authors.initials: C
authors.lastname: Pannetier
authors.forename: A
authors.initials: A
authors.lastname: Steinle
authors.forename: T
authors.initials: T
authors.lastname: Wolfel
authors.forename: D
authors.initials: D
authors.lastname: Lienard
authors.forename: V
authors.initials: V
authors.lastname: Brichard
authors.forename: A
authors.initials: A
authors.lastname: van Pel
authors.forename: F
authors.initials: F
authors.lastname: Jotereau
authors.forename: J C
authors.initials: JC
authors.lastname: Cerottini
mesh_terms: D000595:Amino Acid Sequence; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D001483:Base Sequence; D002999:Clone Cells / Q000276:immunology; D015329:Gene Rearrangement, T-Lymphocyte; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D016056:Immunodominant Epitopes / Q000235:genetics / Q000276:immunology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D058965:MART-1 Antigen; D008545:Melanoma / Q000276:immunology*; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology*; D017354:Point Mutation; D011485:Protein Binding; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics; D013379:Substrate Specificity; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D015789:HLA-A2 Antigen; D016056:Immunodominant Epitopes; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins; D016693:Receptors, Antigen, T-Cell, alpha-beta